Privia Health Group, Inc. (PRVA) Stock Price & How to Invest

Privia Health Group is a national physician-enablement company headquartered in Arlington, Virginia, and its structure is unusual enough that it drives everything about the financials. Physicians keep owning their own Affiliated Practices and the buildings, staff and equipment inside them, and they join a single large Privia Medical Group in their market as owners of it. Privia holds the payer contracts, negotiates reimbursement, maintains the patient records and supplies the Privia Platform (technology plus revenue-cycle, population-health and administrative services) through a local management services organization, and in states where corporate ownership of medical practice is restricted the Medical Group is a Non-Owned or Friendly entity that Privia manages but does not own. As of June 30, 2026 that network covered ~5,644 implemented providers, ~1,300 practices, ~6.1 million patients and ~1,647,000 attributed lives in value-based arrangements. Revenue arrives in three shapes: fee-for-service patient care (~$803.8 million in the first half of 2026, about ~65% of the total) plus administrative fees from Non-Owned groups, value-based revenue split across capitation (~$181.3 million), shared savings (~$143.9 million) and per-member-per-month care management fees (~$38.6 million), and a small amount of other services. Of every dollar of revenue, roughly ~79% goes straight back out as provider expense to the physicians who earned it.

The investment picture is a fast compounder priced against two very different earnings numbers. For the twelve months ended June 30, 2026 Privia collected ~$3.69 billion of Practice Collections, reported ~$2.36 billion of GAAP revenue (up ~24% year over year), retained ~$503 million of Care Margin and produced ~$144 million of adjusted EBITDA against ~$28 million of GAAP net income attributable to stockholders. That ~$116 million gap is mostly non-cash stock compensation, which ran ~$41.3 million in the first half of 2026 alone and helped push shares outstanding from ~123.6 million to ~126.3 million in six months. Second-quarter 2026 results were strong on both bases: revenue ~$632.6 million (up ~21.4%), adjusted EBITDA ~$37.4 million (up ~29.1%), platform contribution margin ~52.2% versus ~49.9%, and management raised full-year 2026 guidance to the high end on Practice Collections (~$3.75 billion) and GAAP revenue (~$2.45 billion) with adjusted EBITDA now expected at the mid-to-high end of ~$145 million to ~$155 million. At ~$21.12 per share on August 21, 2026 the ~127.7 million shares carry a market value near ~$2.70 billion, and with ~$412.2 million of cash and no debt the enterprise value is roughly ~$2.29 billion, or about ~16x trailing adjusted EBITDA and ~96x trailing GAAP earnings. The stock sits closer to its ~$19.53 52-week low than its ~$28.82 high despite the guidance raise, which is the tension worth understanding.

Payer concentration is the sharpest exposure: three payers accounted for ~27%, ~18% and ~17% of first-half revenue, and a single payer represented ~55% of net receivables at June 30, 2026, so one contract renegotiation or slow settlement moves both the income statement and the cash cycle. Cash flow itself is lumpy in a way the annual figure hides, because operating activities used ~$48.4 million in the first half of 2026 (versus ~$16.1 million used in the prior-year half) as accounts receivable built by ~$172.4 million ahead of shared-savings settlements, even though full-year 2025 operating cash flow was positive at ~$163.4 million. On March 24, 2026, after making a voluntary disclosure, Privia received a Request for Information or Assistance from the Department of Health and Human Services Office of Inspector General regarding a single former obstetric and gynecological Affiliated Practice in the Mid-Atlantic and whether it procured and implanted medical devices without complying with applicable requirements; the company is cooperating with OIG, the Department of Justice and the Virginia Attorney General, says it is unaware of similar conduct elsewhere, and does not currently expect a material adverse effect, but the scope is not yet determined. Structurally, most of the economics belong to the doctors (provider expense is ~79% of revenue), the physicians are independent and can leave, and the terms of Medicare Shared Savings, capitated and commercial value-based programs are set by CMS and payers rather than by Privia, so a rule change can reprice the fastest-growing revenue line. Finally, the valuation carries no cushion on reported earnings at roughly ~96x trailing GAAP net income, and closing the gap to the ~$1.04 of trailing adjusted EPS requires accepting ~$71.1 million of annualized stock compensation as a non-expense while the share count keeps rising.

18 analysts publish price targets on PRVA, averaging $31.67 against a $21.12 price as of August 2026, or +50.0%. The published targets run from $24.00 to $40.00, a moderate spread, and the ratings split 18 buy, 1 hold, 0 sell. Over the last six months there have been 3 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PRVA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Privia Health Group, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Provider adds and new-market entry drive the top line. Implemented providers reached ~5,644 at June 30, 2026, up ~10.1% year over year, and management kept full-year guidance at ~5,900 to ~6,000. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. Payer concentration is the sharpest exposure: three payers accounted for ~27%, ~18% and ~17% of first-half revenue, and a single payer represented ~55% of net receivables at June 30, 2026, so one contract renegotiation or slow settlement moves both the income statement and the cash cycle. The most pessimistic target, $24.00, is roughly what PRVA is worth if this bites instead.

Read the full bull and bear case on PRVA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Privia Health Group, Inc.'s investor relations page or your broker.

• Practice Collections vs revenue (TTM): Practice Collections ~$3.69 billion flowed through the platform, of which ~$2.36 billion was recognized as GAAP revenue; the difference is collections at Non-Owned Medical Groups that Privia manages but does not consolidate. Full-year 2026 guidance was raised to the high end at ~$3.65 to ~$3.75 billion of collections and ~$2.35 to ~$2.45 billion of revenue
• Revenue growth: GAAP revenue ~$2.36 billion for the twelve months ended June 30, 2026, up ~24%; Q2 2026 revenue ~$632.6 million, up ~21.4%; first-half revenue ~$1.24 billion, up ~23.5%, split ~65% fee-for-service patient care and ~29% value-based (capitation, shared savings, care management fees)
• What Privia keeps: Provider expense consumed ~79% of Q2 revenue (~$500.5 million of ~$632.6 million). Trailing Care Margin ~$503 million (~13.6% of Practice Collections, ~21% of revenue), platform contribution ~$69.0 million in Q2 at a ~52.2% margin, and trailing adjusted EBITDA ~$144 million, roughly ~3.9% of the money flowing across the platform
• Earnings, GAAP versus adjusted: Trailing net income attributable to stockholders ~$28.1 million (~$0.22 per share) against trailing adjusted net income of ~$136 million (~$1.04 per diluted share). The bridge is ~$71.1 million of annualized stock compensation plus intangible amortization and non-recurring items; Q2 2026 net income was ~$9.0 million with ~$19.4 million of stock compensation inside it
• Balance sheet and cash: ~$412.2 million cash and no debt against ~$1.49 billion of total assets and ~$838.1 million of total equity; ~$541.4 million of the ~$650.5 million of liabilities is provider liability owed onward to practices. Operating activities used ~$48.4 million in the first half of 2026 on a ~$172.4 million receivable build, versus ~$163.4 million generated in full-year 2025
• Market pricing: ~$21.12 per share on August 21, 2026 for a market value near ~$2.70 billion on ~127.7 million shares, an enterprise value near ~$2.29 billion after cash. That is ~96x trailing GAAP earnings, ~20x trailing adjusted EPS, ~1.1x GAAP sales, ~0.7x Practice Collections, ~4.6x Care Margin and ~16x trailing adjusted EBITDA (~15x the mid-to-high end of ~$145 to ~$155 million guided for 2026); 52-week range ~$19.53 to ~$28.82

Figures are approximate, stamped to August 2026 and drawn from the Q2 2026 earnings release, the Form 10-Q filed August 6, 2026 and the full-year 2025 release, so verify live data before acting on any of them. The reason PRVA screens at ~1.1x sales and ~96x earnings simultaneously is that the sales figure includes the ~79% of revenue paid straight to physicians while the earnings figure is after ~$71 million of annual stock compensation, so neither multiple describes the business on its own. The cleanest single comparison is enterprise value against adjusted EBITDA at roughly ~16x trailing and ~15x guided, held next to ~24% revenue growth, ~19% attributed-lives growth and a debt-free balance sheet.

Other names that sit close to PRVA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get PRVA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so PRVA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PRVA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Privia is a debt-free, asset-light aggregator of independent physicians growing collections and attributed lives at double digits, whose economics only make sense line by line, since the headline collections number is roughly ~26 times the adjusted EBITDA it actually produces.

Whether PRVA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PRVA a buy or a sell?, and where the stock could go from here in the PRVA stock forecast.

For income investors, whether PRVA pays a dividend and how the payout looks is covered in does PRVA pay a dividend? And to weigh PRVA against a peer, read the full side-by-side comparisons: PRVA vs AGL and PRVA vs ASTH.